| Patents for A61P 29 - Non-central analgesic, antipyretic or antiinflammatory agents, e.g antirheumatic agents; Non-steroidal antiinflammatory drugs (nsaids) (127,169) |
|---|
| 09/26/2002 | WO2002074913A2 Nucleic acid-associated proteins |
| 09/26/2002 | WO2002074805A1 Soluble rage protein |
| 09/26/2002 | WO2002074798A2 The genome of a bifidobacterium |
| 09/26/2002 | WO2002074784A2 Novel use of a peptide class of compound for treating non neuropathic inflammatory pain |
| 09/26/2002 | WO2002074780A1 Chemical compounds |
| 09/26/2002 | WO2002074773A1 Imidazo-pyrimidine derivatives as ligands for gaba receptors |
| 09/26/2002 | WO2002074772A1 Imidazo-pyrimidine derivatives as ligands for gaba receptors |
| 09/26/2002 | WO2002074771A1 Tricyclic heterocyclic compound, process for producing the same, and use |
| 09/26/2002 | WO2002074770A1 Triazaspiro[5.5]undecane derivatives and drugs containing the same as the active ingredient |
| 09/26/2002 | WO2002074767A1 Metalloproteinase inhibitors |
| 09/26/2002 | WO2002074765A1 Phenyl derivatives 3 |
| 09/26/2002 | WO2002074763A1 Benzimidazol derivatives modulate chemokine receptors |
| 09/26/2002 | WO2002074761A1 Substituted n-arylsulfonyl-proline derivatives as potent cell adhesion inhibitors |
| 09/26/2002 | WO2002074758A2 Novel amines as histamine-3 receptor ligands and their therapeutic applications |
| 09/26/2002 | WO2002074754A1 New spirotricyclic derivatives and their use as phosphodiesterase-7 inhibitors |
| 09/26/2002 | WO2002074752A1 Metalloproteinase inhibitors |
| 09/26/2002 | WO2002074751A1 Metalloproteinase inhibitors |
| 09/26/2002 | WO2002074750A1 Metalloproteinase inhibitors |
| 09/26/2002 | WO2002074749A1 Metalloproteinase inhibitors |
| 09/26/2002 | WO2002074748A1 Metalloproteinase inhibitors |
| 09/26/2002 | WO2002074743A1 Aryl-substituted alicyclic compound and medical composition comprising the same |
| 09/26/2002 | WO2002074735A2 Biurethane derivatives |
| 09/26/2002 | WO2002074733A2 Tryptase-inhibitors |
| 09/26/2002 | WO2002074730A1 INHIBITORS OF INTEGRIN αvβ¿6? |
| 09/26/2002 | WO2002074726A2 Aniline derivatives useful as phosphodiesterase 4 inhibitors |
| 09/26/2002 | WO2002074725A1 Novel ligands of nuclear receptor superfamily, process for producing the same and use thereof |
| 09/26/2002 | WO2002074346A2 Targeting chemical compounds to cells |
| 09/26/2002 | WO2002074328A1 Methods of treating respiratory conditions |
| 09/26/2002 | WO2002074326A2 Urocortin-iii and uses thereof |
| 09/26/2002 | WO2002074323A2 Using neural thread proteins to treat tumors and other hyperproliferative disorders |
| 09/26/2002 | WO2002074320A1 Agastache rugosa extract and composition containing tilianin isolated and purified from said extract having anti-inflammatory activity and anti-atherogenic activity |
| 09/26/2002 | WO2002074318A1 Il-12 expression controlling agents |
| 09/26/2002 | WO2002074307A1 Treatment of restenosis |
| 09/26/2002 | WO2002074301A1 Method of using pyruvate and/or its derivatives for the treatment of cytokine-mediated inflammatory conditions |
| 09/26/2002 | WO2002074298A1 Il-6 production inhibitors |
| 09/26/2002 | WO2002074292A2 Hormone replacement therapy |
| 09/26/2002 | WO2002074282A1 New composition |
| 09/26/2002 | WO2002074231A2 Cosmetic and dermopharmaceutical compositions comprising standardised extracts of hierochloe odorata |
| 09/26/2002 | WO2002074056A2 Allosteric adenosine receptor modulators |
| 09/26/2002 | WO2002062999A8 Proteins and nucleic acids encoding same |
| 09/26/2002 | WO2002060900A3 Antagonists of mcp-1 function and methods of use thereof |
| 09/26/2002 | WO2002055517A3 4-(hetero)aryl substituted indolinones |
| 09/26/2002 | WO2002046214A3 Immunomodulatory protein derived from the yaba monkey tumor virus |
| 09/26/2002 | WO2002032872A8 Nitrogenous aromatic ring compounds |
| 09/26/2002 | WO2002026954A3 Truncated phosphodiesterase-7 polypeptides |
| 09/26/2002 | WO2002024636A3 N-acylsulfonamide apoptosis promoters |
| 09/26/2002 | WO2002003975A3 Combinations of ssri and estrogenic agents |
| 09/26/2002 | WO2002000710A3 B7-like molecules and uses thereof |
| 09/26/2002 | WO2001098332A3 Secreted redox proteins |
| 09/26/2002 | WO2001087343A3 Combination therapy using cox-2 selective inhibitor and thromboxane inhibitor and compositions therefor |
| 09/26/2002 | WO2001083775A3 Proteases |
| 09/26/2002 | WO2001076568A3 Use of 13-hode as a regulator of vascular biocompatibility and an inhibitor of cell hyperplasia |
| 09/26/2002 | WO2001072695A1 Neovascularization inhibitors |
| 09/26/2002 | WO2001052847A8 Thiazole, imidazole and oxazole compounds and treatments of disorders associated with protein aging |
| 09/26/2002 | WO2001019823A9 Substituted pyridino pentaazamacrocyle complexes having superoxide dismutase activity |
| 09/26/2002 | US20020138860 Novel uses of mammalian CCR6 receptors and related reagents |
| 09/26/2002 | US20020138857 Transgenic animals expressing antibodies specific for genes of interest and uses thereof |
| 09/26/2002 | US20020137961 Use as skin lightening agents; 4-(1,4-Dioxaspiro(4.5)dec-8-yl)-1,3-benzenediol for example |
| 09/26/2002 | US20020137941 Bicyclic signal transduction inhibitors, compositions containing them & uses thereof |
| 09/26/2002 | US20020137932 Treating autoimmune diseases, Alzheimer's disease, atherosclerosis, osteoporosis, and asthma |
| 09/26/2002 | US20020137801 Administering gossypol; kits to treat patients |
| 09/26/2002 | US20020137800 2-cyclopenten-1-one and its derivatives as inhibitors of the NF-kB factor |
| 09/26/2002 | US20020137782 Amide substituted benzimidazole or benzoxazole; regulating the interaction of vascular cell adhesion molecule-1 and fibronectin with the integrin vascular cell adhesion molecule very late antigen-4 |
| 09/26/2002 | US20020137778 Anticancer, antiarthritic, and antiinflammatory agents |
| 09/26/2002 | US20020137755 Tyrosine kinase inhibitors |
| 09/26/2002 | US20020137750 Amidine derivatives which are inhibitors of nitric oxide synthase |
| 09/26/2002 | US20020137749 Formulation for menopausal women |
| 09/26/2002 | US20020137745 N-(3,5-dichloropyridin-4-yl)-2-(1-(4-fluorobenzyl)-5 -hydroxyindol-3-yl)-2-oxoacetamide, for example; treating eosinophil-related conditions, including chronic obstructive pulmonary disease |
| 09/26/2002 | US20020137744 Metalloprotease inhibitors |
| 09/26/2002 | US20020137740 CRF (corticotropin releasing factor) antagonists; 4-(2-Chloro-4-methoxyphenyl)-5-methyl-2-(N-(5-ethoxy-carbonyl-2 -methoxyphenyl)-N-propylamino)thiazole for example |
| 09/26/2002 | US20020137687 Novel compounds that inhibit tryptase activity |
| 09/26/2002 | US20020137686 Inhibitors of the ICE/ced-3 family of cysteine proteases |
| 09/26/2002 | US20020137676 Selective treatment of endothelial somatostatin receptors |
| 09/26/2002 | US20020137184 Isolated human protease proteins, nucleic acid molecules encoding human protease proteins, and use thereof |
| 09/26/2002 | US20020137138 Modulating serotonin activity |
| 09/26/2002 | US20020137134 Genetic engineering; glycoproteins |
| 09/26/2002 | US20020136819 Conserved concentrations of cocoa polyphenols by mixing carbohydrate or protein containing ingredients with a polyphenol conserving pretreatment ingredient and then with a cocoa polyphenol |
| 09/26/2002 | US20020136784 Cyclooxygenase-2 (COX-2); administering a plant extract; nonsteroidal anti-inflammatory agents |
| 09/26/2002 | US20020136753 Oolong tea extract; antiinflammatories, anti-atopic dermatitis agent or antipsoriatic agent |
| 09/26/2002 | US20020136724 Methods for treating rheumatoid arthritis using IL-17 antagonists |
| 09/26/2002 | US20020136720 Methods of using IMXP-888 and IMXP-888 antagonists |
| 09/26/2002 | US20020136719 For biomedical applications, including biological delivery to humans and animals |
| 09/26/2002 | US20020136717 Process for screening chemical compounds for modulating the interaction of an EVH1 domain or a protein having an EVH1 domain with an EVH1 binding domain or a protein having an EVH1 binding domain, and a process for detecting said interaction |
| 09/26/2002 | DE10113402A1 New N,N'-bis-(Aminocarbonyl)-hydrazine derivatives are Factor Xa and Factor VIIa inhibitors useful e.g. for treating thrombosis, myocardial infarction, inflammation, apoplexy, restenosis or tumors |
| 09/26/2002 | DE10112771A1 New 3-acylamino-3-phenyl-propionic acid derivatives, are integrin inhibitors useful e.g. for treating thrombosis, cardiac infarction, angina pectoris, tumor diseases, inflammation, osteoporosis or infections |
| 09/26/2002 | DE10112068A1 Use of sulfonylguanidine derivatives, mostly new compounds, for treating e.g. pain and neurodegeneration, have affinity for the gabapentin binding site |
| 09/26/2002 | CA2444526A1 Metalloproteinase inhibitors |
| 09/26/2002 | CA2442268A1 Benzimidazol derivatives modulate chemokine receptors |
| 09/26/2002 | CA2441563A1 Allosteric adenosine receptor modulators |
| 09/26/2002 | CA2441427A1 Biurethane derivatives |
| 09/26/2002 | CA2441202A1 Chemical compounds |
| 09/26/2002 | CA2441155A1 Methods of treating respiratory conditions |
| 09/26/2002 | CA2441152A1 Hormone replacement therapy |
| 09/26/2002 | CA2441111A1 Method for targeting chemical compounds to cells and pharmaceutical compositions used therein |
| 09/26/2002 | CA2440956A1 Oligonucleotides for regulating the gene coding for tnf.alpha. and/or genes controlled thereby and use thereof |
| 09/26/2002 | CA2440954A1 Phenyl derivatives 3 |
| 09/26/2002 | CA2440632A1 Metalloproteinase inhibitors |
| 09/26/2002 | CA2440631A1 Metalloproteinase inhibitors |
| 09/26/2002 | CA2440482A1 Tryptase-inhibitors |
| 09/26/2002 | CA2440480A1 Method of using pyruvate and/or its derivatives for the treatment of cytokine-mediated inflammatory conditions |